98%
921
2 minutes
20
The repair of bone defects remains a huge clinical challenge. M2 macrophage-derived exosomes (M2-Exos) can act as immunomodulators to promote fracture healing; however, how to retain the sustained release of exosomes to the target area remains a challenge. Here, we report a composite hydrogel loaded with M2-Exos aiming to accelerate bone defect healing. It was verified that the F127/HA-NB hydrogel had a dense network structure, tissue adhesiveness, and dual sensitivity to temperature and light. F127/HA-NB loaded with M2-Exos (M2-Exos@F127/HA-NB) exhibited good biocompatibility and achieved sustained release of exosomes for up to two weeks. The study showed that both M0-Exos and M2-Exos@F127/HA-NB significantly promoted osteogenic differentiation of rat bone marrow mesenchymal stem cells. The mechanism study implied that M2-Exos activates the Wnt/β-catenin signaling pathway to promote osteogenic differentiation of BMSCs. Finally, we evaluated the osteogenetic effects of M2-Exos@F127/HA-NB in a rat cranial defect model, and the results showed that M2-Exos@F127/HA-NB had superior bone regeneration-promoting effects. This study provides a new strategy for cell-free treatment of bone defects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701361 | PMC |
http://dx.doi.org/10.1016/j.mtbio.2023.100840 | DOI Listing |
Adv Healthc Mater
September 2025
State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, Wuhan, 430070, P. R. China.
Osteoarthritis (OA) is a common degenerative joint disease, and early diagnosis and effective treatment are essential for managing its progression. This study focuses on the development of a novel drug delivery system using aggregation-induced emission (AIE) probe for enhanced fluorescence imaging and targeted therapy in OA. TPE-S-BTD, an AIE probe, is synthesized and characterized for its photophysical properties, demonstrating significant aggregation-induced fluorescence enhancement.
View Article and Find Full Text PDFTurk J Pharm Sci
September 2025
Gate Institute of Pharmaceutical Sciences, Telangana, India.
Objectives: Bortezomib (BTZ) functions as an androgen receptor signalling inhibitor, is used for the treatment of prostate cancer, and has been sanctioned by the United States Food and Drug Administration. The medicinal applications of BTZ are impeded by low solubility, first-pass metabolism, and restricted bioavailability. This study aimed to develop and enhance polylactic acid-co-glycolic acid (PLGA) nanobubbles (NBs) as a sustained-release mechanism for BTZ, thereby augmenting stability and bioavailability.
View Article and Find Full Text PDFBrain
September 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Guangdong Provincial Key Laboratory of Non-human Primate Research, Guangdong-Hong Kong-Macau Institute of CNS Rege
Abnormal accumulation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Small interfering RNAs (siRNAs) targeting TDP-43 offer potential therapeutic strategies for these diseases. However, efficient and safe delivery of siRNAs to the central nervous system (CNS) remains a critical challenge.
View Article and Find Full Text PDFJ Hazard Mater
September 2025
Department of Environmental & Sustainable Engineering, University at Albany, State University of New York, Albany, NY 12222, United States. Electronic address:
This study examined the behavior of six U.S. Environmental Protection Agency (EPA) regulated per- and polyfluoroalkyl substances (PFAS) compounds in vegetated soils amended with Class A and Class B biosolids.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
Research Center for Nano-Biomaterial, Analytical and Testing Center, Sichuan University, Chengdu 610065, China.
Regeneration of infected bone defects (IBDs) requires biomaterials capable of dynamically coordinating antimicrobial, anti-inflammatory, and osteogenic functions. Overcoming the spatiotemporal mismatches in treating IBDs remains a critical challenge. Here, we designed a temporally controlled therapy based on gelatin methacrylate (GelMA)-based nanocomposite hydrogels (GCS) coembedded with sulfur quantum dots (SQDs) nanoenzymes and calcium-phosphorus oligomers (CPOs.
View Article and Find Full Text PDF